D Molecular Therapeutics, Inc.’s FDMT share price has dipped by 5.25%, which has investors questioning if this is right time to buy.

The FDA’s Oncologic Drugs Advisory Committee (ODAC) is planning to host its first meeting under new agency commissioner Marty ...

Portfolio Receipts growth of 17% to $839 million; Royalty Receipts growth of 12%Net cash provided by operating activities of $596 millionRaised full year 2025 guidance: Portfolio Receipts expected to ...

Learn about April 2025’s top biotech deals, featuring major collaborations in bispecific antibodies, protein therapies, and ...

Britney Spears keeps wilding but now it's getting dangerous for the former star Gene Hackman's sprawling New Mexico estate, once valued at nearly $5 million, is making headlines for all the wrong ...

Fundraising efforts have helped jump-start gene therapy that could help patients regardless of mutation. While it likely won’t be available for years, “just to have these therapies in trials p ...